Veldrol

Quick links to important sections

Veldrol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Veldrol

Property Description
Active ingredient Tramadol hydrochloride
Form Oral tablet, Oral capsule, Oral solution, Injectable solution
Pharmacological class Opioid analgesic, Centrally acting analgesic
Common use Relief of moderate to moderately severe pain
Origin Synthetic compound

What Type of Analgesic is Veldrol?

Veldrol is a medication whose active component is Tramadol hydrochloride, and it is defined as a centrally acting opioid analgesic. This designation means the drug primarily works within the central nervous system—the brain and spinal cord—to manage and interrupt the perception of pain signals, providing relief for moderate to moderately severe discomfort. Tramadol is effective for treating moderate pain through its unique dual mechanism of action, which involves both engaging opioid receptors and modulating neurotransmitters. This medicine helps ease discomfort by utilizing two distinct, complementary pathways in the central nervous system. Unlike traditional opioids, Tramadol's classification as an atypical opioid arises from this combination of mechanisms, setting it apart from classic, single-mechanism pain relievers.

Veldrol's Composition and Origin

The core substance of Veldrol is Tramadol, a synthetic compound that is entirely manufactured through chemical processes, not derived from a natural source like the opium poppy. Veldrol is a single-ingredient product containing Tramadol hydrochloride as the sole active pharmaceutical ingredient. Clinically recognized for its efficacy, Tramadol is commonly available under various brand names, such as Ultram, ConZip, and Tramal. Tramadol is administered as a racemic mixture, a blend of two mirror-image molecules that contribute to its complex pain-relieving profile. The drug's composition is a precise chemical mixture designed to maximize its analgesic effect.

What Forms Does Veldrol Come In?

The active ingredient, Tramadol hydrochloride, is prepared in several pharmaceutical forms to allow for its systemic delivery, primarily via the oral route of administration. These preparations commonly include various types of oral tablets, such as immediate-release (IR) and extended-release (ER) forms, with the ER forms offering the differentiating feature of sustained relief over many hours. Beyond oral administration, Tramadol may also be formulated as an injectable solution for parenteral use in specific healthcare settings.

What side effects are possible with Veldrol?

Possible Side Effects and Safety Information

The safety profile for Veldrol (Tramadol hydrochloride) is formally categorized in regulatory documentation based on frequency and affected body systems. Adverse reactions are classified using standard frequency bands defined by governmental health authorities.

Frequency-Classified Adverse Reactions

The most frequently reported effects, designated as Very Common (more than 10% of patients), include nausea and dizziness. Reactions classified as Common (1% to 10% of patients) typically involve the gastrointestinal and nervous systems, such as somnolence (sleepiness), constipation, headache, and vomiting. Less frequent reactions, categorized as Rare (0.01% to 0.1% of patients), span multiple organ systems and include respiratory depression, seizures (convulsions), and hallucinations.

Serious Safety Considerations

The official labeling notes several serious adverse reactions. These include the risk of life-threatening respiratory depression, the potential for Serotonin Syndrome—especially when used with other serotonergic medicines—and rare but serious anaphylactoid reactions. Furthermore, repeated use, even at therapeutic doses, carries a risk of developing tolerance, physical dependence, and Opioid Use Disorder.

Population-Specific Safety Notes

Specific safety constraints are documented for certain populations. Veldrol is contraindicated in children younger than 12 years of age and in those with documented severe hepatic or renal impairment. Additionally, the risk of life-threatening respiratory depression is heightened in children identified as ultra-rapid metabolizers. Use during breastfeeding is generally not recommended due to potential harm to the infant.

Overdose and Emergency Response

Veldrol overdose is defined in regulatory documents as a severe, potentially life-threatening event requiring immediate medical attention. Documented manifestations center on the Central Nervous System (CNS), Respiratory System, and Cardiovascular System. Presentations include profound somnolence, stupor, or coma, along with respiratory depression which can lead to respiratory arrest. Additional severe outcomes include seizures (convulsions), circulatory collapse, and the risk of Serotonin Syndrome.

In case of suspected overdose, regulators mandate that immediate medical help must be sought. Life-threatening signs such as slow breathing, loss of consciousness, or signs of circulatory compromise require urgent contact with emergency services. The accidental ingestion of any amount, particularly by pediatric patients, is considered a critical, potentially fatal overdose event.

Overdose management is primarily symptomatic and supportive treatment. While Naloxone may be used to reverse the opioid-induced respiratory depression, regulatory documents note it may only partially address the overall toxic effects. Establishing a patent airway and instituting assisted ventilation are essential steps described in official protocols.

Therapeutic Uses of Veldrol

What Veldrol Treats: Main Uses and Benefits

Veldrol is commonly used for managing symptoms related to physical discomfort of moderate to moderately severe intensity. This medication is applied across domains where additional symptomatic support is needed, primarily for conditions presenting with acute or recurrent manifestations.

This medication is relevant for easing symptoms associated with postoperative pain, discomfort associated with post-traumatic or post-surgical events, and long-term musculoskeletal pain syndromes. It is applied when symptoms create noticeable physiological strain and cannot be adequately managed by standard alternatives. Its use may assist with supportive relief during both acute episodes and for sustained support against chronic symptom patterns.

“It provides support that helps ease the overall symptom burden, particularly when symptoms become more disruptive.”

Veldrol plays a role in managing symptoms that may become intense or disruptive, offering symptomatic relief that helps improve day-to-day comfort and assists with maintaining functional stability when symptoms interfere with routine activities.


Quick Fact: Relief for Moderate to Moderately Severe Pain


Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility profile for Veldrol (Tramadol hydrochloride) is strictly defined by government regulatory agencies. The medicine is indicated for use in adults for pain management, and conditionally in adolescents 12 to 18 years of age who do not possess specific respiratory risk factors.

Contraindicated Populations (Must Not Use)

Category Contraindication
Age Children younger than 12 years of age; adolescents under 18 post-tonsillectomy/adenoidectomy.
Comorbidity Severe respiratory depression, acute severe asthma, uncontrolled epilepsy.
History/Other Known hypersensitivity to tramadol, acute intoxication (e.g., alcohol), or concurrent use of Monoamine Oxidase Inhibitors (MAOIs).

Restricted or Not Recommended Use

Use is not recommended in patients with severe renal impairment or severe hepatic impairment due to the risk of impaired drug clearance. Veldrol is not recommended during pregnancy (risk of Neonatal Opioid Withdrawal Syndrome) or lactation. Additionally, use requires special caution for patients over 75 years of age and those with a history of seizure disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Veldrol (Tramadol) is defined by official regulatory documents, primarily focusing on pharmacodynamic risk and metabolic pathway interference. The product is contraindicated for co-administration with Monoamine Oxidase Inhibitors (MAOIs), requiring a 14-day separation period after the MAOI is stopped.

Pharmacodynamic Interactions

Co-administration with other substances that act on the central nervous system (CNS) is officially restricted due to the potential for severe additive effects. Combining Veldrol with CNS Depressants (including alcohol, benzodiazepines, and other opioids) carries a documented risk of profound sedation and respiratory depression. Use with serotonergic drugs (such as SSRIs or Triptans) or drugs that lower the seizure threshold is also associated with an increased risk of Serotonin Syndrome or seizure activity, respectively.

Pharmacokinetic Interactions

Officially documented pharmacokinetic interactions occur via the Cytochrome P450 enzymes ( CYP2D6 and CYP3A4), which affect the clearance and concentration of Veldrol and its active M1 metabolite. CYP2D6 Inhibitors (e.g., fluoxetine) increase Veldrol exposure but decrease the active M1 metabolite, potentially reducing efficacy. Conversely, CYP3A4 Inducers (e.g., carbamazepine) decrease the overall exposure of Veldrol and M1, which is officially documented as leading to a reduced analgesic effect. Additionally, co-use with Warfarin has been associated with officially reported alterations to the International Normalized Ratio (INR).

Mechanism of Action

Dual Action on Opioid Receptors and Neurotransmitters

The mechanism of Veldrol involves two complementary actions within the central nervous system: first, the drug and its active form bind to mu-opioid receptors (MOR) on nerve cells, acting as an agonist to alter signaling. Second, the drug acts as an inhibitor on the Serotonin (SERT) and Norepinephrine Transporters (NET), which results in an increased concentration of these chemical messengers in the synapse.


Alteration of the Descending Inhibitory Pathway

The simultaneous engagement of these two targets enhances activity within the descending inhibitory pathway, a pathway involved in the suppression of nociceptive signaling in the spinal cord. By suppressing the activity of neurons involved in afferent (incoming) signal transmission and enhancing activity within the inhibitory pathway, the drug's mechanism results in the alteration of nociceptive signal transmission and processing within the central nervous system.

Dosage and Administration Information

The administration of Veldrol (Tramadol hydrochloride) is governed by protocols that define specific routes, dose limits, and required handling procedures. The medication is approved for oral intake as immediate-release (IR) or extended-release (ER) tablets, capsules, and solutions. It is also approved for parenteral use via intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection, typically in healthcare settings.


Dosing and Administration Parameters

Entity Instruction
Dosing Schedule The standard IR dose is 50 mg to 100 mg every 4 to 6 hours, not to exceed 400 mg/day. ER formulations are administered 100 mg once daily, with a maximum limit of 300 mg/day.
Timing in relation to meals All oral formulations may be taken with or without food.
Formulation-Specific Handling ER tablets and capsules must be swallowed whole and must not be crushed, split, chewed, or dissolved. The injectable solution may require dilution before intravenous infusion.
Population Adjustments For adults over 75 years using IR forms, the maximum daily dose is restricted to 300 mg. Patients with severe renal impairment must have their IR dosing interval extended to 12 hours with a 200 mg daily limit; ER is generally not recommended in this group.
Course Duration & Cessation Use must be for the shortest duration consistent with the treatment goals. When discontinuing after long-term use, the dose must be gradually tapered to prevent withdrawal symptoms.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Veldrol


Evidence for Veldrol in Acute Pain Conditions

The active ingredient in Veldrol, Tramadol, was evaluated in research exploring how symptoms change over time following acute physical events, such as after surgical procedures or injuries. These studies were primarily short-term randomized controlled trials (RCTs). Researchers applied standardized tools to measure outcomes related to physical discomfort, and studies monitored how symptom intensity evolved in the observed populations over the first few days.

Studies report measurements observed related to short-term symptom changes. Findings describe patterns observed in the studies, with research highlighting changes measured during the study period, particularly concerning patient-reported perceived discomfort. The studies also describe measurements of the need for additional pain relief medication in the hours following the initial dose of the active ingredient. There is limited information for long-term outcomes following acute use, as follow-up durations were limited.


Evidence for Veldrol in Chronic Non-Cancer Pain

The active ingredient in Veldrol was evaluated in randomized controlled trials (RCTs), many lasting a few months, and in comprehensive systematic reviews applied in studies examining patient-reported experiences for conditions such as osteoarthritis and chronic low back pain. These studies explored outcomes reflecting daily functioning or activity level, alongside patient-reported outcomes describing perceived discomfort.

Research examined changes measured during the study period for outcomes related to physical discomfort and functional capacity. Findings were also mixed across the collected evidence. Data for long-term outcomes are still emerging, as follow-up durations were limited across many key studies. Evidence quality varies across studies, and findings were often heterogeneous (inconsistent) when examined in systematic reviews.


Studies in Special Patient Populations and Research Gaps

Tramadol was studied for use in older adults, with research examining how symptoms change over time in this population group. However, data for certain groups remain insufficient. For instance, limited information is available for use in pediatric populations, and evidence describing group patterns for pregnant individuals remains insufficient.

In summary, the evidence landscape highlights several limitations, including the limited follow-up durations in many pivotal trials, meaning the long-term effects are not fully established. Additionally, research is needed regarding some complex chronic pain outcomes.

Frequently Asked Questions (FAQ)

Common questions about Veldrol (FAQ)


Q: How quickly does Veldrol start to make a difference?

According to official product information, immediate-release formulations of Veldrol usually begin to provide pain relief within one hour of administration. The full effect of these forms is often observed within two to three hours. Extended-release formulations are designed to work over a longer period, resulting in a slower onset but prolonged relief.


Q: What happens if I accidentally miss a dose of Veldrol?

Regulatory documents advise that if a dose is missed, it is recommended to skip the missed dose entirely. The next dose should then be taken at the regularly scheduled time. Patients should not take a double dose to make up for a missed one, as this action carries a risk of harm.


Q: How long can a person safely stay on Veldrol?

Studies on Veldrol have typically been controlled for periods of up to three months of continuous use. For treatment beyond this duration, regulatory documents state that use should be regularly reviewed by a prescriber to confirm that ongoing treatment remains appropriate and necessary. Use should be for the shortest duration consistent with treatment goals.


Q: Are there any specific supplements that should be avoided with Veldrol?

Official information warns against taking Veldrol with other medicines or products known to affect the central nervous system or increase serotonin levels. While not a complete list, it is important that prescribers are aware of all herbal remedies and supplements being taken due to the potential for interactions, especially those that could interfere with the way Veldrol is metabolized by the body.


Q: What should I do if a side effect of Veldrol feels really bad?

For any severe reactions, such as symptoms of a serious allergic reaction, breathing difficulties, or a seizure, emergency medical attention should be sought immediately. If other severe or worrisome side effects occur, it is generally recommended to consult the healthcare provider before making any changes to the treatment plan.


Q: Can I stop taking Veldrol if I feel better?

Discontinuing Veldrol should only be done under the direction of a healthcare provider. Stopping the medication suddenly after a prolonged period is not recommended. Official guidance states that the dose must be gradually tapered over time to help prevent potential withdrawal symptoms.


Q: Can Veldrol be taken with herbal remedies like St. John's Wort?

The official labeling advises against co-use with substances known to affect serotonin levels. Combining these products, which includes serotonergic supplements like St. John's Wort, carries an increased risk of a serious condition called Serotonin Syndrome. The use of any herbal products should be discussed with the prescriber before starting Veldrol to prevent potential interactions.


Q: Is Veldrol known to cause dry mouth?

Yes, regulatory information indicates that dry mouth (xerostomia) is a commonly reported side effect of Veldrol. It is officially classified as an effect that occurs in a small percentage of patients (up to 10%) in clinical trials.


Q: Are side effects of Veldrol worse when first starting the medicine?

Official patient information indicates that some of the common side effects, such as nausea and dizziness, may be more noticeable when treatment is first initiated. These effects often become less severe or may resolve entirely as the body adjusts to the medication, typically within the first one or two weeks.


Q: What is the main difference between Veldrol and [similar drug class name]?

Veldrol is classified as an atypical opioid analgesic because it utilizes a dual mechanism of action. Unlike traditional opioids that primarily target pain receptors, Veldrol also works by affecting the brain's natural messengers, serotonin and norepinephrine, giving it a unique pain-relieving profile.


Q: Can Veldrol cause changes in mood or personality?

The official label notes that Veldrol may cause central nervous system side effects. These psychiatric effects can include agitation, confusion, anxiety, and, in rare instances, more severe reactions like hallucinations or changes in mood.


Q: What if I take Veldrol, but I don't feel any changes?

If no pain relief is experienced after a few weeks, it is not recommended to make any changes without professional guidance. Consultation with a healthcare provider is necessary to assess whether an adjustment in the treatment plan may be needed, as the dose should not be increased without professional direction.


Q: Are generic versions of Veldrol available, and are they the same?

Yes, the active ingredient in Veldrol, Tramadol hydrochloride, is widely available in generic formulations. Official regulatory agencies require that generic versions must meet the same strict standards as the brand name product for their strength, quality, and overall performance.


Q: What should be done if I get a rash after starting Veldrol?

A rash can be a sign of a severe allergic or hypersensitivity reaction to the medicine. If a rash or other signs of an allergic reaction develop after starting Veldrol, immediate medical attention is required according to official guidance.


Q: What's the typical duration of treatment with Veldrol?

For all uses, Veldrol should be used for the shortest duration necessary to achieve treatment goals. While short-term use is common for acute pain, studies for chronic conditions typically followed patients for a few months, requiring regular evaluation for continued use.


Q: Can Veldrol cause issues with concentration or memory?

Yes, official safety information indicates that Veldrol may affect mental functions. Side effects like somnolence (sleepiness) and dizziness can potentially impair concentration and physical abilities, which is why caution is advised for tasks requiring mental alertness.

How should Veldrol be stored and disposed of?

Veldrol, containing Tramadol hydrochloride, must be stored according to official regulatory labeling to ensure stability and prevent accidental exposure.

Item Requirement
Storage Temperature Store at Controlled Room Temperature (20^circ to 25 C / 68^circ to 77 F), with permitted excursions up to 30 C / 86 F.
Protection and Container Protect from moisture; keep the product in its original container and keep tightly closed.
Child Safety Keep out of the sight and reach of children due to the serious risk of fatal overdose from accidental ingestion.
Disposal Instructions Unused or expired product must be disposed of via a drug take-back program. If a take-back option is not immediately accessible, the FDA directs that it must be immediately flushed down the toilet.

The required storage conditions maintain the medication's effectiveness until its expiration date. The stringent child-protection and disposal instructions are mandatory due to the medication's opioid nature and the high risk of harm from unintended access or misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Veldrol found in:

A-Z Index: